VPT:CC - Ventripoint Unveils New Integrated Product with ASCEND Cardiovascular
(TheNewswire)
Toronto, Ontario – TheNewswire –August 18, 2023 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company "), (TSXV:VPT ) ( OTC:VPTDF) isthrilled to announce that Ventripoint and ASCEND Cardiovascular, LLC have developed a new integrated product. Today’s announcementmarks a significant milestone in Ventripoint’s commitment to thecollaboration between the two companies. ASCEND fits perfectly intoVentripoint’s roadmap for innovation and is a key step in thecompany’s mission to improve patient’s lives and become thestandard of care.
ASCEND is seamlessly integrated with leading EHRs, andimaging systems. Their existing technology has been installed at1000+ top ranked healthcare facilities and 600+ health systems withapproximately 50,000 users across the United States.
Ventripoint has successfully and seamlessly integratedits specialized AI-powered 3D Echo software application withASCEND’s diagnostic viewer, InView, and reporting application,Cardiovascular Structured Reporting. This cardiovascular workflowproduct provides an end-to-end solution that rivals other products onthe market. It is streamlined, smart, and effective for cardiologyreading, reporting, and diagnostics, thereby improving diagnosis andmonitoring of fetal, pediatric, and adult congenital heart disease.
“We are excited to embark on this collaborativejourney with ASCEND Cardiovascular,” stated Dr. Alvira Macanovic,President & CEO of Ventripoint Diagnostics. “We see thiscollaboration evolving progressively in its possibilities. Webelieve that by integrating Ventripoint’s technology in diagnosticmedical imaging with ASCEND’s expertise in cardiology IT this willbe a successful integrated product. The product will offer a seamlessand comprehensive approach to diagnosing and treating cardiovascularconditions.”
After months of development, Ventripoint stands readyto successfully unveil this integrated product with its newest partnerat the 8 th World Congress of Pediatric Cardiology and Cardiac Surgeryin Washington, DC later this month.
"This is an important milestone and validation ofASCEND’s commitment to providers caring for children with heartdisease. We are excited to enable the routine, efficient use ofVentripoint's advanced 3D image analysis in pediatriccardiology," stated Dr. Jeff Soble, CEO of ASCEND.
As the collaboration between Ventripoint and ASCENDcontinues to evolve, both companies remain committed to drivinginnovation and excellence in cardiovascular health technology. Thisintegrated product marks an exciting milestone in the advancement ofcardiac care and solving today’s and anticipating tomorrow’schallenges.
About Ventripoint DiagnosticsLtd.
Ventripoint has become known forthe application of AI (Artificial Intelligence) to echocardiography.Ventripoint's VMS products are powered by its proprietary AItechnology, which is the result of a decade of development andprovides accurate volumetric cardiac measurements equivalent to MRI.Ventripoint's VMS products are powered by its proprietary KBRtechnology, which is the result of a decade of development andprovides accurate volumetric cardiac measurements equivalent to MRI.This affordable, gold-standard alternative allows cardiologistsgreater confidence in the management of their patients. Providingbetter care to patients serves as a springboard and basic standard forall of Ventripoint's products that guide our future developments. Inaddition, VMS+ is versatile and can be used with all ultrasoundsystems from any vendor supported by regulatory market approvals inthe U.S., Europe and Canada. Learn more: www.ventripoint.com .
About ASCEND Cardiovascular
ASCEND Cardiovascular is a leader in innovatingcardiovascular solutions that empower the provider community toimprove cardiovascular care. Designed with openness in mind, theirsolutions integrate with EHRs, medical devices, and other systems todeliver seamless workflows that span procedure types and modalities. Acomplete cardiovascular solution, ASCEND provides structuredreporting, image visualization, collaboration, and analytics thatimprove efficiency, outcomes, and ROI. With decades of experience anda practicing cardiologist at our helm, the ASCEND team bringsunparalleled “know how” in cardiology workflow, collaboration, andIT offering limitless opportunities to improve clinical, operational,and quality performance. Learn more: www.ascendcv.com .
For further information, pleasecontact:
Jonathan Robinson CFA
(416) 669-1001
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placedon the forward-looking statements and information because the Companycan give no assurance that they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2023 TheNewswire - All rights reserved.